Klotho Neurosciences为ALS准备基因疗法,目的是在Q3 2026进行病人试验。 Klotho Neurosciences prepares gene therapy for ALS, aiming for patient trials by Q3 2026.

Klotho Neurosciences正在开发KLTO-202,这是ALS的基因疗法,使用阿尔法-Klotho基因的独特RNA组合变体。 Klotho Neurosciences is developing KLTO-202, a gene therapy for ALS, using a unique RNA splice variant of the alpha-Klotho gene. 这一变体在动物研究中显示具有神经防护性,在进入临床试验之前,将进行制造和过程开发。 This variant, shown to be neuroprotective in animal studies, will undergo manufacturing and process development before entering clinical trials. 该公司计划在2026年第三季度之前开始对ALS病人进行基因治疗研究,与合同研究组织合作有效管理这一进程。 The company plans to begin gene therapy studies in ALS patients by the third quarter of 2026, working with contract research organizations to manage the process efficiently.